Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK1 | Q15118 | 17/20 | 0.67 |
| ▸ | PDK2 | Q15119 | 17/20 | 0.67 |
| ▸ | PDK3 | Q15120 | 17/20 | 0.67 |
| ▸ | PDK4 | Q16654 | 17/20 | 0.67 |
| ▸ | ABCC9 | O60706 | 2/20 | 0.52 |
| ▸ | ABCC8 | Q09428 | 2/20 | 0.52 |
| ▸ | KCNJ11 | Q14654 | 2/20 | 0.52 |
| ▸ | KCNJ8 | Q15842 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27010697 | 0.84 | RAB9A (0.55) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL4610634 | 0.84 | PDK1 (0.65) | PDK1PDK2PDK3PDK4ABCC9 | |
| SCHEMBL6569974 | 0.82 | PDK1 (0.62) | PDK1PDK2PDK3PDK4ABCC9 | |
| SCHEMBL6569632 | 0.82 | PDK1 (0.62) | PDK1PDK2PDK3PDK4 | |
| SCHEMBL6347722 | 0.81 | PDK1 (0.73) | PDK1PDK2PDK3PDK4ABCC9 | |
| SCHEMBL4610185 | 0.81 | PDK1 (0.60) | PDK1PDK2PDK3PDK4ABCC9 | |
| SCHEMBL6347970 | 0.80 | PDK1 (1.00) | PDK1PDK2PDK3PDK4ABCC9 | |
| SCHEMBL6350423 | 0.79 | PDK1 (0.64) | PDK1PDK2PDK3PDK4ABCC9 | |
| SCHEMBL6350542 | 0.79 | PDK1 (0.64) | PDK1PDK2PDK3PDK4ABCC9 | |
| SCHEMBL4623429 | 0.79 | ABCC9 (0.76) | PDK1PDK2PDK3PDK4ABCC9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6960688-B2 | Use of compounds for the elevation of pyruvate dehydrogenase activity | ASTRAZENECA AB (SE) | 2005-11-01 | — | — | US | disclosed |
| EP-1082110-B1 | USE OF COMPOUNDS FOR THE ELEVATION OF PYRUVATE DEHYDROGENASE ACTIVITY | ASTRAZENECA AB (SE) | 2004-03-24 | — | — | EP | disclosed |
| US-20040009979-A1 | Use of compounds for the elevation of pyruvate dehydrogenase activity | ZENECA LIMITED | 2004-01-15 | — | — | US | disclosed |
| US-6498275-B1 | Use of compounds for the elevation of pyruvate dehydrogenase activity | ASTRAZENECA AB (SE) | 2002-12-24 | — | — | US | disclosed |
| EP-1082110-A1 | USE OF COMPOUNDS FOR THE ELEVATION OF PYRUVATE DEHYDROGENASE ACTIVITY | AstraZeneca AB (SE) | 2001-03-14 | — | — | EP | disclosed |
| WO-1999062506-A1 | USE OF COMPOUNDS FOR THE ELEVATION OF PYRUVATE DEHYDROGENASE ACTIVITY | ASTRAZENECA AB (SE) | 1999-12-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009979-A1 | Use of compounds for the elevation of pyruvate dehydrogenase activity | PDHA1, PDK1, PDHB | PDK1 2/4885PDK2 8/4885PDK3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.